2,578 reports of this reaction
2.0% of all SODIUM OXYBATE reports
#13 most reported adverse reaction
SLEEP APNOEA SYNDROME is the #13 most commonly reported adverse reaction for SODIUM OXYBATE, manufactured by Jazz Pharmaceuticals, Inc.. There are 2,578 FDA adverse event reports linking SODIUM OXYBATE to SLEEP APNOEA SYNDROME. This represents approximately 2.0% of all 126,117 adverse event reports for this drug.
SODIUM OXYBATE has an overall safety score of 85 out of 100. Patients taking SODIUM OXYBATE who experience sleep apnoea syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SLEEP APNOEA SYNDROME is a less commonly reported adverse event for SODIUM OXYBATE, but still significant enough to appear in the safety profile.
In addition to sleep apnoea syndrome, the following adverse reactions have been reported for SODIUM OXYBATE:
The following drugs have also been linked to sleep apnoea syndrome in FDA adverse event reports:
SLEEP APNOEA SYNDROME has been reported as an adverse event in 2,578 FDA reports for SODIUM OXYBATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SLEEP APNOEA SYNDROME accounts for approximately 2.0% of all adverse event reports for SODIUM OXYBATE, making it a notable side effect.
If you experience sleep apnoea syndrome while taking SODIUM OXYBATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.